How Public–Private Partnerships Could Boost Domestic Device Output

India’s healthcare industry stands at a strategic inflection point. The market, valued at more than $372 billion in 2022, could surpass $500 billion by 2030, but 70 percent of its medical devices are still imported. Hospitals rely on foreign technology even as local innovators struggle to scale. The missing bridge between government policy and industry capability lies in public–private partnerships (PPPs)-a model that can convert intent into industrial depth and achieve the goal of 'Make in India' for the health sector.

Why PPPs Matter for the Healthcare Sector

The medical devices market in India is unlike most manufacturing segments: it sits at the intersection of healthcare access, R&D, and global regulation. Governments manage policy, pricing, and public procurement; private firms handle innovation, production, and service. When these two spheres operate in silos, national capacity lags.

A PPP approach can align incentives: the public sector provides infrastructure, demand assurance, and regulatory predictability; private players contribute capital, technology, and speed. Together they can close the 60–70 percent import gap that weakens the healthcare sector in India.

Core PPP Models for MedTech Manufacturing

PPPs in MedTech don't follow a single template. India needs to deploy hybrid models that best suit the complexity and capital requirements of the sector:

1. Build-Own-Operate-Transfer (BOOT): The private partner builds manufacturing or testing facilities on public land, operates them for a set period, and then transfers ownership back to the government. This is ideal for establishing certified testing centres or common infrastructure in Medical Device Parks.
2. Clinical Service Models: Private firms manage and maintain high-end equipment (like MRI or CT scanners) within public hospitals, ensuring maximum uptime and trained personnel, while the public sector assures a minimum patient load and affordability.
3. Co-Development and Procurement: The government co-funds R&D for a specific device needed in public health (e.g., affordable ventilators) and, in return, guarantees a large-volume, long-term purchase commitment to the private manufacturer upon successful validation.

The Current Gap Between Policy and Production

India already offers strong policy instruments-PLI schemes, Medical Device Parks, and the Promotion of Research & Innovation in Pharma-MedTech (PRIP) program-but most remain under-utilised because coordination stops at funding. Many startups lack access to certified testing centres, while large OEMs hesitate to invest without long-term procurement visibility.

A structured PPP can change this dynamic by linking incentives with actual off-take-governments guaranteeing volume through hospital networks and private partners ensuring quality and delivery. This shift moves the focus from subsidizing production to guaranteeing demand based on quality.

Global Precedents India Can Learn From

Countries such as South Korea and Singapore built robust medical-technology clusters by pairing government research institutes with private manufacturers. The UK's NHS Innovation Accelerator helps scale clinician-driven inventions through co-funding and clinical trials in public hospitals, effectively using the vast public health system as a "test-bed" for domestic innovations.

For India, adopting a similar model-state-backed clinical validation, public hospital test-beds, and shared IP frameworks-could multiply domestic device output within five years. A powerful example is the Coalition for Epidemic Preparedness Innovations (CEPI), a global PPP that demonstrates how governments and private pharma/tech firms can pool resources to accelerate R&D and manufacturing for critical needs.

Building India’s MedTech Clusters Through PPPs

The country’s four Medical Device Parks in Noida, Telangana, Tamil Nadu, and Himachal Pradesh already provide the skeleton for collaboration. The next step is attracting private anchor tenants-device makers, component suppliers, and digital-health startups-through joint-venture models.

Public agencies can offer land, plug-and-play infrastructure, and concessional finance, while private firms build production and training facilities. Each cluster should integrate hospitals, engineering colleges, and testing labs to shorten the path from prototype to patient and address the significant skill gap identified in the industry.

Accelerating Innovation and Clinical Validation

One of India’s biggest bottlenecks is the “prototype-to-product” gap. Promising devices often stall before regulatory approval because startups cannot afford multi-site clinical trials or navigate the complex Medical Devices Rules, 2017. PPPs can solve this by creating national validation networks:

• Clinical Test-Beds: Public hospitals provide necessary patient data and trial infrastructure under standardized protocols.
• Regulatory Fast-Track: Devices developed under a specific PPP framework that meet pre-agreed quality standards (like ISO 13485:2016) can receive expedited approvals from the CDSCO (Central Drugs Standard Control Organisation).

This co-development framework can fast-track approvals and improve post-market surveillance-critical for both investor confidence and hospital adoption.

Financing Models for Shared Risk

Traditional grants cannot sustain long-cycle device development. India needs hybrid instruments that distribute risk:

• Outcome-Based Contracts: Payment to the private partner is tied to performance metrics, such as device uptime, patient outcomes, or reduction in total cost of ownership, rather than a fixed upfront cost.
• Innovation Funds: Dedicated PPP-led funds that co-invest in high-risk, high-reward devices (e.g., robotics, advanced imaging) with a clear exit strategy linked to public procurement.
• Lease-to-Own Procurement: Governments commit to leasing equipment for five to seven years with an option to purchase, enabling private firms to secure bank financing against the long-term lease agreement.

This government commitment to buying validated domestic devices for five years encourages banks and venture funds to lend against secured demand, unlocking private capital.

Digital Integration: A Force Multiplier

PPPs will gain even more traction when integrated with India’s health-data infrastructure. The Ayushman Bharat Digital Mission (ABDM) already connects hospitals, labs, and insurers through interoperable health IDs. Locally made, FHIR-ready devices can feed data directly into this ecosystem, enabling:

• Real-Time Monitoring: For predictive maintenance and quality control of devices.
• AI-Driven Research: Large-scale, anonymized patient data can drive next-generation device design tailored to Indian demographics.

Such connectivity transforms PPPs into Digital Public Goods-where public standards meet private innovation, ensuring transparency, traceability, and trust.

Training and Talent Development

Manufacturing output will rise only if skilled technicians, engineers, and biomedical specialists keep pace. The current system often lacks coordination between biomedical education and core engineering. PPPs can address this by:

• Co-designing Curricula: Jointly creating specialized MedTech manufacturing and maintenance courses with institutes like NIPER and IITs.
• Establishing Industry-Academia Co-labs: Setting up simulation and testing labs within universities, fully funded and equipped by private partners.
• Dual Education System: Replicating models from countries like Germany, blending classroom theory with paid, factory-floor apprenticeships in Device Parks to ensure a steady pipeline of job-ready talent.

Overcoming Key Implementation Challenges

For PPPs to succeed, India must proactively mitigate common pitfalls:

Conclusion

Public–private partnerships offer India the most direct route to MedTech self-reliance. They merge the government’s reach with industry’s speed, translating policy intent into manufacturing capacity. When aligned with ABDM’s digital rails and value-based procurement, PPPs can cut import dependence, enhance affordability, and future-proof the healthcare industry in India.

At GrowthJockey, we see similar synergies driving enterprise transformation. Acting as a venture architect, we help organizations bridge policy, technology, and execution-leveraging Intellsys.ai actionable insight for marketers for analytics. The lesson is clear: collaboration beats competition. India’s MedTech future will be built by partnerships that unite vision, capital, and accountability.

FAQs

Q1. What is the role of public–private partnerships in healthcare?

They combine government policy, infrastructure, and funding with private-sector efficiency and innovation to expand access and quality in a sustainable, risk-shared manner.

Q2. How can PPPs boost medical device manufacturing in India?

By sharing infrastructure, co-financing R&D, creating clinical test-beds for validation, and linking public procurement with private production targets, PPPs create crucial demand assurance and reduce market risk.

Q3. What challenges could PPPs face?

Bureaucratic delays, uneven risk-sharing, and unclear accountability are key challenges. These are mitigated by long-term contracts, clear performance KPIs, and third-party risk appraisal.

Q4. How can digital health platforms enhance PPPs?

Integration with ABDM and FHIR-ready devices enables data transparency, real-time outcomes monitoring, and AI-driven research, transforming PPPs into Digital Public Goods.

Q5. What economic impact can localized device output have?

It can reduce imports by $3–4 billion, create high-skill jobs, and position India as a global export hub for affordable health technology, contributing to allied sectors like precision engineering and IT.